Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03719885 · ClinicalTrials.gov registry record · NA
TrueTear in Sjogren's Disease Patients
A NA study of Sjogren's Syndrome and Dry Eye Syndromes, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT03719885 is a NA study of Sjogren's Syndrome and Dry Eye Syndromes that has completed, run by University of Pennsylvania. The registered enrollment target is 55 participants, below the 286-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03719885, a NA study of Sjogren's Syndrome and Dry Eye Syndromes, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate acute tear production produced by the intranasal tear neurostimulator in participants with Sjögrens syndrome and aqueous tear deficiency. Our primary goal is to evaluate whether Sjögrens patients respond to this intervention and whether there is a baseline tear production level below which these patients do not respond.
Conditions Studied
Interventions
- DEVICE TrueTear Intranasal Tear Neurostimulator
Study Locations (1)
Pennsylvania
- Scheie Eye Institute, University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2019-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03719885
The ClinicalTrials.gov registry entry for NCT03719885 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 286-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (81% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sjogren's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which TrueTear Intranasal Tear Neurostimulator is the first listed.
NCT03719885 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03719885 about?
NCT03719885 is a clinical study titled "TrueTear in Sjogren's Disease Patients". The purpose of this study is to evaluate acute tear production produced by the intranasal tear neurostimulator in participants with Sjögrens syndrome and aqueous tear deficiency. Our primary goal is to evaluate whether Sjögrens patients respond to this intervention and whether there is a baseline te...
What is the current status of trial NCT03719885?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2018-12-01. Estimated completion is 2019-12-31.
What conditions does trial NCT03719885 study?
This clinical trial studies the following conditions: Sjogren's Syndrome, Dry Eye Syndromes.
What interventions are being tested in trial NCT03719885?
The interventions under investigation include: TrueTear Intranasal Tear Neurostimulator (DEVICE).
Who is sponsoring clinical trial NCT03719885?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03719885 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjogren's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Rheumatology Diet Study
RECRUITING
-
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
RECRUITING · Phase 1
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
-
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
RECRUITING · Phase 2
-
Characterization of Diseases With Salivary Gland Involvement
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.